S
ometimes the role of CFO is less about
instituting reforms than identifying when
something is working, and then getting
out of the way. Robert Landry, who
took on the position of CFO for Regeneron
Pharmaceuticals Inc. last October, has learned
the value of both approaches over his 26 years in
the pharma/biopharmaceutical industry, holding
a variety of finance positions. As he has settled
into his latest role — his first as CFO of a publicly
traded company —Landry sums up his strategy
as: “Be an enabler, not a blocker.
“We never know where the next great piece of
science or technology is coming from— someone
could walk in one day and say, ‘We just did this
intriguing study within our discovery group,
but I don’t have the budget for further experi-
ments,’ so it’s my job to enable these scientists
Raising the
Biopharma Bar
REGENERONCFOROBERT LANDRY IS USINGHIS
BIG PHARMA BACKGROUNDTOHELP
AN INNOVATIVE COMPANY GROW
14
2nd QUARTER 2014
FEATURED
CFO
BY ALEX PALMER
